Gilead Acquires NASH Candidate from Nimbus to Strengthen its Liver Disease Portfolio
By Taskin Ahmed & Keshav Mahawar
Pharma Deals Review: Vol 2016 Issue 4 (Table of Contents)
Published: 21 Apr-2016
DOI: 10.3833/pdr.v2016.i4.2155 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
A year after acquiring Phenex’s farnesoid X receptor (FXR) agonist to boost its non-alcoholic steatohepatitis (NASH) portfolio, Gilead Sciences has struck another deal to acquire Nimbus Apollo for its acetyl-CoA carboxylase (ACC) inhibitor programme and lead asset, NDI-010976, which is ready to enter Phase II clinical trials for the treatment of NASH...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS